Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations

June 07, 2011
Top Quote Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that a Phase III study (BRIM3) showed vemurafenib (RG7204, PLX4032) significantly improved overall survival (OS) in people with previously untreated BRAF V600 mutation-positive metastatic melanoma, compared to chemotherapy. End Quote
  • (1888PressRelease) June 07, 2011 - In the study, the risk of death was reduced by 63 percent for people who received vemurafenib compared to those who received chemotherapy (hazard ratio [HR]=0.37, p

    ###
space
space
  • FB Icon Twitter Icon In-Icon
Contact Information
Over Satisfied Users & Approved Press Releases
© Copyright 2005-2025, 1888 Press Release. All Rights Reserved